Related Experiment Videos
First Clinical Experience Using Stereotactic Breast Biopsy Guided by 99mTc-Sestamibi
Angela Collarino1,2, Renato A Valdés Olmos1,3,4, Peter A Neijenhuis5
11 Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
AJR. American Journal of Roentgenology
|April 6, 2017
Summary
A new molecular breast imaging (MBI) device for technetium-99m sestamibi-guided biopsy is effective for breast lesion localization and diagnosis. This complementary tool proved technically feasible in 38 women, aiding in identifying malignant and benign tumors.
Area of Science:
- Radiology
- Oncology
- Medical Devices
Background:
- Accurate breast lesion diagnosis is crucial for effective cancer treatment.
- Molecular breast imaging (MBI) offers functional information for lesion detection.
- Stereotactic biopsy is a standard method for tissue sampling.
Purpose of the Study:
- To evaluate a novel MBI-based device for technetium-99m sestamibi-guided stereotactic lesion localization.
- To assess its utility as a complementary tool in breast lesion biopsy.
Main Methods:
- Retrospective review of 38 women undergoing MBI-guided biopsy with a new device.
- Procedure involved lesion localization, coordinate calculation, needle placement, verification, and vacuum-assisted tissue sampling.
- Radiologic marker placement and ex vivo specimen measurement were performed.
Main Results:
- The procedure was technically successful in all 38 lesions.
- Biopsy samples were adequate for histopathology; 50% of lesions were malignant.
- Mean procedure time was 71 minutes; marker deployment success rate was 97%.
Conclusions:
- Technetium-99m sestamibi-guided biopsy using the dedicated MBI device is technically feasible.
- This MBI-based approach is a valuable complementary tool for breast lesion diagnosis.